Impact of oral contraceptives and metformin on advanced lipid phenotyping in polycystic ovary syndrome
Authors:
Open Access
- 3 August 2026
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (2) , 302-311
Abstract
Context: Combined oral contraceptives (OCPs) and metformin are commonly used in patients with polycystic ovary syndrome (PCOS), who are at elevated risk of dyslipidemia and cardiovascular disease (CVD), but their effects on advanced lipid phenotyping remain unclear. Objective: To examine the impact of OCPs and metformin on (1) lipoproteins, (2) apolipoproteins, and (3) cholesterol efflux capacity (CEC, marker of HDL function). Design: Secondary analysis of the COMET-PCOS randomized clinical trial. Setting: Two tertiary care reproductive endocrinology clinics. Patients or Other Participants: Patients with hyperandrogenic PCOS and elevated BMI with paired serum samples for lipoprotein/apolipoprotein analysis (n = 180) and cholesterol efflux capacity (n = 129). Intervention(s): 24 weeks of metformin, OCP, or OCP + metformin. Main Outcome Measure(s): Change in HDL particles (HDL-P), low-density lipoprotein particles (LDL-P), triglyceride-rich lipoprotein particles (TRL-P); apolipoproteins A-I, B, and C-III; and CEC. Results: HDL-P concentration increased in the OCP and OCP + metformin arms, while atherogenic small LDL-P increased slightly. Metformin had a largely neutral effect on advanced lipid phenotyping. Cholesterol efflux capacity increased in the OCP arm, though this was attenuated when adjusting for change in ApoA-I (adjusted ratio of geometric means 1.08, 95% CI 0.99-1.17), which increased in all arms. Conclusions: In patients with PCOS and high metabolic risk, OCP use resulted in improved HDL-C function and a mixed effect on lipoproteins and apolipoproteins, with no clear benefit from metformin. These findings do not support or refute the cardiovascular risk-benefit of OCP use in PCOS and highlight the need for studies evaluating long-term clinical outcomes.Keywords
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD091350)
This publication has 31 references indexed in Scilit:
- Association of polycystic ovary syndrome with atherosclerotic cardiovascular disease eventsFertility and Sterility, 2025
- Quantifying Triglyceride-Rich Lipoprotein Atherogenicity, Associations With Inflammation, and Implications for Risk Assessment Using Non-HDL CholesterolJACC, 2024
- Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering TherapiesJACC, 2023
- Different Pathways of Cellular Cholesterol EffluxCell Biochemistry and Biophysics, 2022
- Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasisAtherosclerosis, 2012
- Lipid levels in polycystic ovary syndrome: systematic review and meta-analysisFertility and Sterility, 2011
- Clinical implications of discordance between low-density lipoprotein cholesterol and particle numberJournal of Clinical Lipidology, 2011
- Metformin restores impaired HDL-mediated cholesterol efflux due to glycationAtherosclerosis, 2009
- A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestinsAmerican Journal of Obstetrics and Gynecology, 1993
- A randomized comparative open study of the effects of two oral contraceptives, triphasil and ortho 7/7/7, on lipid metabolismContraception, 1993